These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall
Moderna could tumble once again, if there’s a lack of positive news in its upcoming earnings release. Novo…
Trump’s $150 Ozempic? Oz cautions it’s not a done deal, but patients and doctors say it could be a gamechanger
Janet McCaskill was on vacation in Arizona with her husband and best friend when she heard that President…
3 Top Healthcare Stocks to Buy in October
Novo Nordisk could get its momentum back with its oral Wegovy pill. Danaher is a proven market-beater trading…
Exclusive-Bill Gates, PAHO consider ways to bring weight-loss drugs to lower-income countries
By Jennifer Rigby LONDON (Reuters) -The Gates Foundation and the Pan American Health Organization are both working on…
50 European corporates backing startups on the path to growth, innovation, and global impact
Across Europe, big companies are becoming strong backers of startup innovation, and corporate venturing is widely used as…
Fat-loss drug Mounjaro now India’s No. 2 pharma brand | India News
NEW DELHI: Soaring demand for weight-loss therapies has brought Eli Lilly’s Mounjaro within striking distance of Indian pharma…
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…
Ozempic maker urges Ottawa to shut down online drug sales to Americans
OTTAWA — Novo Nordisk, the Danish drug company that makes Ozempic and Wegovy, wants the Canadian government to…
GLP-1 Weight-Loss Pills Could Transform Treatment
A new era of weight-loss treatment could soon trade needles for pills. Drugmakers behind GLP-1 injections like Wegovy…
How the ‘Ozempic effect’ is reshaping the global economy
Michael Siluk/Alamy The new wave of weight-loss drugs has taken the world by storm. From Novo Nordisk’s Ozempic…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…